Spinraza (nusinersen) is a brand-name injection prescribed for spinal muscular atrophy in adults and children. As with other drugs, Spinraza can cause side effects, such as fever, headache, and ...

Biogen Inc BIIB announced new Spinraza (nusinersen) data that were presented at the SMA Research & Clinical Care Meeting hosted by Cure SMA. RESPOND is an ongoing two-year, phase 4 open-label study to ...

The new data show that an axonal injury and neurodegeneration biomarker was reduced in nearly all study participants treated with Spinraza. The evaluates clinical outcomes and safety following ...

CARLSBAD, Calif., June 30, 2023 /PRNewswire/ -- Ionis Pharmaceuticals (Nasdaq: IONS) today announced that its partner Biogen presented new data highlighting the potential benefit of SPINRAZA® ...

Topline data from an ongoing clinical trial of a higher dose regimen of Spinraza in treatment-naive, symptomatic infants with spinal muscular atrophy showed significantly improved motor function at 6 ...

The cost of Spinraza injection can vary based on several factors, including your insurance coverage. Coupons and drug savings programs can also lower the price you’ll pay for Spinraza. As with all ...

Over the last decade, three blockbuster drugs—Biogen’s Spinraza, Roche’s Evrysdi and Novartis’ gene therapy Zolgensma—have transformed the treatment landscape for spinal muscular atrophy (SMA).

Biogen has partnered with Alcyone Therapeutics to improve the delivery of its spinal muscular atrophy drug Spinraza, handing over $10 million upfront for a global license to an implantable device.

CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced interim 6-month biomarker data from the initial 29 participants in the open-label RESPOND study.* The Phase 4 ...

Biogen BIIB announced positive initial data from the pivotal cohort (Part B) of its mid to late-stage study evaluating the safety and efficacy of a higher dose regimen of Spinraza (nusinersen) in ...

Biogen said that new data examining its already approved spinal muscular atrophy treatment Spinraza (nusinersen) indicates that a higher dose than currently approved may lead to better improvement in ...

Biogen said U.S. and European regulators will review its applications seeking approval of a higher-dose regimen of its Spinraza drug for the neuromuscular disease spinal muscular atrophy. The ...